- Home
- NVGS vs SPRY Comparison
NVGS vs SPRY Comparison
Compare NVGS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- SPRY
- Stock Information
- Founded
- NVGS 1997
- SPRY 2015
- Country
- NVGS United Kingdom
- SPRY United States
- Employees
- NVGS N/A
- SPRY N/A
- Industry
- NVGS Marine Transportation
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- SPRY Health Care
- Exchange
- NVGS Nasdaq
- SPRY Nasdaq
- Market Cap
- NVGS 1.1B
- SPRY 1.1B
- IPO Year
- NVGS N/A
- SPRY N/A
- Fundamental
- Price
- NVGS $17.03
- SPRY $12.49
- Analyst Decision
- NVGS Strong Buy
- SPRY Strong Buy
- Analyst Count
- NVGS 3
- SPRY 4
- Target Price
- NVGS $22.00
- SPRY $26.00
- AVG Volume (30 Days)
- NVGS 218.6K
- SPRY 1.4M
- Earning Date
- NVGS 03-12-2025
- SPRY 03-20-2025
- Dividend Yield
- NVGS 1.18%
- SPRY N/A
- EPS Growth
- NVGS 13.48
- SPRY N/A
- EPS
- NVGS 1.12
- SPRY N/A
- Revenue
- NVGS $564,280,000.00
- SPRY $2,568,000.00
- Revenue This Year
- NVGS $0.05
- SPRY $67,363.34
- Revenue Next Year
- NVGS $4.76
- SPRY $511.99
- P/E Ratio
- NVGS $14.81
- SPRY N/A
- Revenue Growth
- NVGS 5.99
- SPRY 8460.00
- 52 Week Low
- NVGS $14.55
- SPRY $6.29
- 52 Week High
- NVGS $18.18
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- NVGS 54.83
- SPRY 44.57
- Support Level
- NVGS $15.92
- SPRY $11.00
- Resistance Level
- NVGS $17.52
- SPRY $14.87
- Average True Range (ATR)
- NVGS 0.45
- SPRY 0.95
- MACD
- NVGS -0.03
- SPRY 0.04
- Stochastic Oscillator
- NVGS 40.62
- SPRY 31.26
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.